BLS Pharmaceuticals
Short position
BLS Pharmaceuticals (ASX:BLS) has 0.01% of its shares on issue reported as short positions as of 5 Oct 2026, or about 13,655 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. BLS is classified in the Household & Personal Products industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4BLS Pharmaceuticals (BLS) financials
Results, ratios and statements
Latest result
Year to 30 Jun 2026 (FY26) vs FY25, figures in AUD, the reporting currency
- Revenue
- $74.2Mvs n/a (FY25)
- Yahoo Finance, as at 29 Sep 2026
- NPAT
- $15.4Mvs n/a (FY25)
- Yahoo Finance, as at 29 Sep 2026
- EPS (diluted)
- $0.067vs $0.021 (FY25)
- Yahoo Finance, as at 29 Sep 2026
- Rev YoY
- n/aFY
- EPS YoY
- n/mTTM
Summary of Annual Report to shareholders, 31 Aug 2026
BLS Pharmaceuticals reported record FY26 revenue of $74.2 million, up 153% from $29.3 million, and net profit of $15.4 million, up 214% from $4.9 million. No dividend was declared or paid. The company achieved results at the top of its upgraded guidance range, with Adjusted EBITDA of $19.0 million and cash of $13.3 million at year end.
Automated summary of the filing; the filing itself is the record.
Key ratios
Year to 30 Jun 2026 (FY); balance sheet at 30 Jun 2026; prices to 9 Oct 2026
- Gross margin
- 56.0%
- Operating margin
- 21.3%
- Net margin
- 20.8%
- FCF margin
- 2.6%
- ROE
- n/a
- ROA
- n/a
- FCF conversion
- 0.13×
- Net cash (excl. leases)
- $10.3M
- Net debt / EBITDA
- −0.6×
- Current ratio
- 2.9×
- Interest cover
- 34.4×
- Cash dividends paid / net profit
- n/a
- Market cap
- $234.6M
- P/E
- 15.2×
- P/B
- 7.5×
Ratios use the reporting currency (AUD); market cap is in AUD. Source: Yahoo Finance, as at 29 Sep 2026.
Financial statements
Figures in AUD, the reporting currency; Yahoo Finance unless marked
| Line item | FY26 | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Revenue | $74.2M | n/a | $9.3M | $5.2M |
| Gross profit | $41.6M | n/a | $3.4M | $1.9M |
| Operating income | $15.8M | n/a | −$1.7M | −$2.1M |
| EBITDA | $17.0M | n/a | −$1.7M | −$2.1M |
| EBIT | $15.6M | n/a | −$1.7M | −$2.1M |
| Interest expense | $460.0K | n/a | n/a | n/a |
| Pretax income | $15.2M | n/a | −$13.0M | −$2.0M |
| Tax | −$239.5K | n/a | $0 | $0 |
| NPAT | $15.4M | n/a | −$13.3M | −$2.0M |
| Net interest income | −$391.8K | n/a | $16.6K | $2.6K |
| EPS basic | $0.069 | $0.024 | −$0.069 | −$0.015 |
| EPS diluted | $0.067 | $0.021 | −$0.069 | −$0.015 |
| Shares | 230.0M | 216.5M | 204.7M | 190.2M |
Financial reports
The company's own filings, newest first
- Annual Report to shareholdersAnnual Report31 Aug 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report27 Jul 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report21 Apr 2026via asx_announcements
- Half Yearly Report and AccountsHalf Year Results26 Feb 2026via asx_announcements
- Bioxyne Webinar Half Year Results Review 26 Feb 11am AEDTHalf Year Results13 Feb 2026via asx_announcements
- Appendix 4C RevisedQuarterly Report28 Jan 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report28 Jan 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report30 Oct 2025via asx_announcements
- Annual Report to shareholdersAnnual Report30 Sep 2025via asx_announcements
- Preliminary Final ReportAnnual Results29 Aug 2025via asx_announcements
Showing 10 of 24 reports